Journal of International Translational Medicine
Citation Search Quick Search Adv Search
Home       Introduction       Editorial Board       Current Issue        Subscribe       Online Publication       About us
Journal of International Translational Medicine
Journal of International Translational Medicine
JITM, ISSN 2227-6394
founded in 2012
Editor-in-chief:Feng Jifeng, China
Open Access
  Instruction for authors
  Online Submission
  Author Guideline
  General Policy
  Copyright Transfer
   Statement
 Conflict of interest
  Disclaimer
  The types of manuscript
  Requirements for
   manuscripts
 
  Reviewing Center
  Peer Review Policy
  Peer Review login
  Editor Work login
  Office Work login
  Editor-in-Chief login
 
  Online Journal
  Accepted
  Online First
 Current Issue
  Archive
  Most Read
  Most Download
  Email Alert
 
Research Highlights More...
Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFRMutated Advanced Non-small Cell Lung Cancer
Yue WANG, Juan NAN
Journal of International Translational Medicine, 2020, 8(2): 27-29
Treatment of Limbal Stem Cell Deficiency in the Setting of Neurotrophic Keratopathy
Rozaliya HRISTOVA1, Yani ZDRAVKOV1, Maria HRISTOVA2, Ivan TANEV1
Journal of International Translational Medicine, 2020, 8(2): 30-37
Neurogenesis is a Proper Target for Controlling Feeding Behavior and Obesity
Hamidreza FAMITAFRESHI1, Morteza KARIMIAN2
Journal of International Translational Medicine, 2020, 8(2): 38-38
 
Current Issue Accepted Online First Archive Most Downloaded
  2020, 8(2)   Published: 24 June 2020
 
Select | Export to Abstract
Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFRMutated Advanced Non-small Cell Lung Cancer Hot!
Yue WANG, Juan NAN
Journal of International Translational Medicine, 2020, 8(2): 27-29 | doi:10.11910/2227-6394.2020.08.02.01
Full Text: PDF (223 KB)    
Show Abstract
The discovery of activating mutations in epidermal growth factor receptor (EGFR) and development of first-/secondgeneration EGFR-tyrosine kinase inhibitors (TKIs) against EGFR sensitive mutations have contributed to a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, drug resistance greatly limits the long-term efficacy of EGFRTKIs. Osimertinib, a third-generation EGFR-TKI, has shown efficacy not only in NSCLC patients who are resistant to firstand second-generation EGFR-TKIs but also in patients with central nervous system metastases. On November 21, 2019, the investigators of the FLAURA trial reported that the NSCLC patients with EGFR mutation who were treated with osimertinib had longer progression-free survival (PFS) than those treated with comparator EGFR-TKIs. However, the data maturity on overall survival (OS) was very low at the time of the primary analysis. In the latest report recently published in The New England Journal of Medicine, the FLAURA team reported the final results of the OS data. They found that first-line osimertinib was associated with significantly longer OS, as compared with comparator regimen, in treating patients with EGFR-mutated advanced NSCLC.
Treatment of Limbal Stem Cell Deficiency in the Setting of Neurotrophic Keratopathy Hot!
Rozaliya HRISTOVA1, Yani ZDRAVKOV1, Maria HRISTOVA2, Ivan TANEV1
Journal of International Translational Medicine, 2020, 8(2): 30-37 | doi:10.11910/2227-6394.2020.08.02.02
Full Text: PDF (488 KB)    
Show Abstract
This study examined the application of cell-based therapy as treatment for severe neurotrophic keratopathy, associated with limbal stem cell deficiency. Autologous limbal epithelial stem cells from ten patients with neurotrophic keratopathy were cultured on human amniotic membrane. Cochet-Bonnet esthesiometry demonstrated reduced to absent corneal sensation. A matrix metalloproteinase-9-based test was used to evaluate ocular surface inflammation. Conjunctivalization of the corneal surface was confirmed on impression cytology. Anterior segment optical coherence tomography was used before and after the intervention. A limbal biopsy was taken from a sector with preserved palisades of Vogt of the affected eye. The harvested limbal stem cells were cultured using a novel explant culture system without xenobiotic products. The grafts were transplanted to the affected eye in 14 days. Success of the procedure was defined as complete epithelialization, reduction of neovascularization, improved corneal transparency, thickness and reflex. Successful ex vivo expansion of the harvested cells was achieved from all biopsies. Clinical recovery was observed in all patients, as well as improvement of subjective ocular comfort. Success criteria were met in all cases. Ocular surface reconstruction in severe neurotrophic keratopathy, associated with limbal stem cell deficiency is possible with cell-based therapy as a safe and effective treatment method.
Neurogenesis is a Proper Target for Controlling Feeding Behavior and Obesity Hot!
Hamidreza FAMITAFRESHI1, Morteza KARIMIAN2
Journal of International Translational Medicine, 2020, 8(2): 38-38 | doi:10.11910/2227-6394.2020.08.02.03
Full Text: PDF (195 KB)    
Show Abstract
JITM Table of Contents Volume 2, Number 2, 2020
Journal of International Translational Medicine, 2020, 8(2): 39-
Full Text: PDF (2199 KB)    
Show Abstract
Journal of International Translational Medicine
 
  Announcement
More...  
  Links
Embase
DOAJ
WANFANG DATA
HuaShi Medical Media
JITM(CNKI)
More...  
   Advertising polices
More...   
 
 
 
Chinese Editorial Department, Journal of International Translational Medicine (English Edition)
Address: Room 201, 203, 205, No.3 Building, Zijin Lianhe Cubic Square, Nanjing, 210037, China
Website:www.jitm.hk E-mail:jitm2012@jitm.hk;TEL:+86-025-85552880,-86- 4000600047